S'abonner

Impact of changes in tobacco smoking prevalence on death, dementia and disability in England and Wales, 2017–2040: A modelling study - 05/07/18

Doi : 10.1016/j.respe.2018.05.014 
S. Ahmadi-Abhari a, , P. Bandosz b, M. Guzman-Castillo b, M. Shipley a, M. O’Flaherty b, E. Brunner a
a Department of Epidemiology & Public Health, University College London, London, United Kingdom 
b Department of Public Health and Policy, University of Liverpool, Liverpool, United Kingdom 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

Background

There is considerable morbidity and mortality associated with smoking globally and in the UK. We aimed to estimate the impact of two scenarios for reduction of smoking prevalence on numbers of deaths, life expectancy and incidence of dementia and disability to 2040 in England and Wales.

Methods

A probabilistic Markov model, IMPACT-BAM, was developed to integrate calendar trends in incidence of cardiovascular disease (CVD), dementia, disability and mortality to forecast future prevalence of these conditions in addition to numbers of deaths from cardiovascular and non-cardiovascular causes in the population of England and Wales. Disability is defined as the inability to independently conduct one or more basic activities of daily living. Data from the English Longitudinal Study of Ageing (ELSA) and Office for National Statistics were used to inform the model. Systematic reviews and meta-analyses of published literature provided relative risks of CVD, dementia, disability and mortality for smokers versus non-smokers, by age and sex. These estimates were used to modify model parameters and forecast the impact of smoking on mortality, dementia and disability to 2040 under three scenarios: S1. Prevalence of smoking remains at 2017 levels, 19% in men and 17% in women, up to 2040 (baseline scenario); S2. Prevalence of smoking is reduced to 9% by 2020 and 5% by 2025 (taper scenario); S3. Smoking is eliminated by 2020 (elimination scenario).

Results

If prevalence of smoking remains at 2017 levels (S1), there will be an estimated 952,000 (95% Uncertainty Interval 808,000–1153,000) deaths from cardiovascular causes and 10,624,000 (9,562,000–11,776,000) deaths from non-cardiovascular causes between 2017 and 2040. If prevalence of smoking declines gradually to 2025 (S2) 35,000 (29,000–43,000) CVD deaths and 408,000 (373,000–443,000) non-CVD deaths could be prevented or postponed. If smoking is eliminated (S3), the corresponding figures are 84,000 (68,000–105,000) and 843,000 (764,000–907,000) deaths. If prevalence of smoking remains constant (S1), cumulatively between 2017 and 2040, 5,073,000 (95%UI 4,868,000–5,256,000) persons are estimated to develop dementia and 6,690,000 (95%UI 6,483,000–6,869,000) persons are estimated to develop disability. 34,000 (22,000–40,000) incident cases of dementia and 57,000 (47,000–73,000) cases of disability can be prevented or postponed under the taper scenario S2. A tot l of 56,000 (17,000–88,000) cases of dementia and 113,000 (52,000–160,000) cases of disability can be prevented or postponed under the elimination scenario S3. Under the stable smoking prevalence scenario (S1) LE at 65 will increase from 21.8 years (95% UI 21.7, 22.0) in 2017 to 26.4 years (95%UI 23.8, 29.9) by 2040. LE at 65 in 2040 is estimated to increase by an additional half a year under S2 (26.9 (24.2, 30.6)) and an additional year under S3 (27.4 [24.5, 31.1]). Half the increase in LE will be free of dementia and disability.

Conclusion

Public health programs targeting tobacco smoking can potentially have a considerable effect on postponing deaths from cardiovascular and non-cardiovascular causes and yield gains in life expectancy free of dementia and disability.

Le texte complet de cet article est disponible en PDF.

Plan


© 2018  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 66 - N° S5

P. S236-S237 - juillet 2018 Retour au numéro
Article précédent Article précédent
  • Do birth cohorts make a difference for deficit accumulation trajectories in older age? First results from the KORA-Age study
  • A.J. Stephan, R. Strobl, R. Holle, M. Christa, K.H. Ladwig, B. Linkohr, B. Thorand, A. Peters, E. Grill
| Article suivant Article suivant
  • Vitamin D as predictor of telomere length in the transition from child to adolescent
  • C. Van Aart, N. Michels, I. Sioen, D. Martens, T. Nawrot, S. De Henauw

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.